Table 2 Prevalence of adjuvant chemotherapy initiation within 9 months of definitive diagnosis, stratified by Oncotype DX recurrence score (ODX RS) and nodal status, among women with HR+/HER2–, early-stage breast cancer who underwent ODX RS testing, n = 248,576.

From: The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment

 

<40 years old

40–69 years old

≥70 years old

N (%)

PR (95% CI)a

N (%)

PR (95% CI)a

N (%)

PR (95% CI)a

Overall

9144 (3.6)

–

196,271 (79.0)

–

43,161 (17.4)

–

ODX RS

Low (≤10)

1737 (19.0)

1.0 (ref.)

53, 922 (27.5)

1.0 (ref.)

13,829 (32.0)

1.0 (ref.)

Intermediate (11–25)

5623 (61.5)

2.48 (2.19, 2.81)

116,613 (59.4)

4.15 (3.97, 4.34)

23,291 (54.0)

4.02 (3.46, 4.67)

High (≥26)

1784 (19.5)

4.94 (4.37, 5.57)

25,736 (13.1)

16.10 (15.40, 16.83)

6041 (14.0)

30.85 (26.73, 35.61)

Nodal statusb

pN0

7630 (83.6)

1.0 (ref.)

164,981 (84.3)

1.0 (ref.)

34,643 (80.7)

1.0 (ref.)

pN1

1496 (16.4)

1.13 (1.10, 1.16)

30,711 (15.7)

1.46 (1.43, 1.48)

8254 (19.2)

1.35 (1.27, 1.43)

  1. PR prevalence ratio, CI confidence interval, ODX RS oncotype DX recurrence score.
  2. aAdjusted for age group, oncotype DX recurrence score, Charlson score, insurance status, grade, cancer type, pathologic T stage; interaction terms between age and ODX RS and nodal status, respectively, were used to get age-stratified effect estimates.
  3. bPatients who had missing staging information were excluded from analysis.
Back to article page